MARKET

APLIF

APLIF

Appili Ther
OTCPK
0.021
NaN%
Closed 09:30 05/16 EDT
OPEN
--
PREV CLOSE
0.021
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.035
52 WEEK LOW
0.020
MARKET CAP
2.52M
P/E (TTM)
-0.9163
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at APLIF last week (0505-0509)?
Weekly Report · 4d ago
Weekly Report: what happened at APLIF last week (0428-0502)?
Weekly Report · 05/05 12:17
Appili Therapeutics Advances Tularemia Vaccine Research
TipRanks · 05/01 12:24
Appili Therapeutics publishes manuscript on emergency response to tularemia
TipRanks · 05/01 11:50
Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
Barchart · 05/01 06:34
Weekly Report: what happened at APLIF last week (0421-0425)?
Weekly Report · 04/28 12:31
Appili Therapeutics Secures New Patents for LIKMEZ, Strengthening Market Position
TipRanks · 04/28 12:12
Appili Therapeutics granted new patents for LIKMEZ
TipRanks · 04/28 11:52
More
About APLIF
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701 and ATI-1801. LIKMEZ (ATI-1501) is its advanced commercial stage asset, a liquid oral reformulation of the antibiotic metronidazole to treat serious anaerobic and protozoal infections. ATI-1701 is a live-attenuated vaccine for Francisella tularensis (F. tularensis), the bacterium which causes tularemia. ATI-1801 is a topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis.

Webull offers Appili Therapeutics Inc stock information, including OTCPK: APLIF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLIF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading APLIF stock methods without spending real money on the virtual paper trading platform.